Different Opioid Drugs Recruit Different Spinal Cord Peptides for Pain Relief
Bremazocine's pain relief involves spinal dynorphin A and met-enkephalin release, while morphine's does not — showing distinct opioid drugs use different spinal pathways.
Quick Facts
What This Study Found
Spinal dynorphin A and met-enkephalin mediate bremazocine's pain relief but not morphine's, showing distinct opioid signaling pathways.
Key Numbers
How They Did This
Researchers injected bremazocine or morphine into mouse brains (intracerebroventricular). They then gave antibodies against specific opioid peptides into the spinal cord to see which peptides were needed for pain relief, measured by the tail-flick test.
Why This Research Matters
This study shows that different opioid drugs recruit different natural pain peptides in the spinal cord. Understanding these distinct pathways could help develop pain treatments with fewer side effects.
The Bigger Picture
If different opioid drugs work through different spinal pathways, combining them might provide better pain relief. And drugs that recruit natural peptides like bremazocine might cause less tolerance than morphine.
What This Study Doesn't Tell Us
This was an animal study in mice using direct brain injection, a route not used in humans. Results may not translate directly to human pain treatment.
Questions This Raises
- ?Could combining bremazocine-type and morphine-type drugs provide synergistic pain relief?
- ?Does recruiting natural spinal peptides cause less tolerance?
Trust & Context
- Key Stat:
- Distinct pathways Bremazocine requires spinal dynorphin A and met-enkephalin release; morphine does not — same brain injection site, completely different spinal mechanisms
- Evidence Grade:
- Preliminary — animal study in mice with brain injection. Elegant pharmacological dissection but limited to one species and acute pain model.
- Study Age:
- Published in 1993 (33 years ago). The concept of multiple opioid analgesic pathways is now well-established.
- Original Title:
- Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.
- Published In:
- The Journal of pharmacology and experimental therapeutics, 266(3), 1430-8 (1993)
- Authors:
- Tseng, L F(8), Collins, K A
- Database ID:
- RPEP-00281
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Why do different opioid drugs use different pathways?
Bremazocine activates epsilon and kappa receptors in the brain, which send signals down the spinal cord that release dynorphin and enkephalin. Morphine primarily activates mu receptors using a different descending pathway. Same starting point, different wiring.
Could this improve pain treatment?
Yes — if drugs recruit non-overlapping spinal pathways, combining them might produce stronger pain relief than either alone, while potentially reducing the tolerance that limits individual drugs.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00281APA
Tseng, L F; Collins, K A. (1993). Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.. The Journal of pharmacology and experimental therapeutics, 266(3), 1430-8.
MLA
Tseng, L F, et al. "Spinal involvement of both dynorphin A and Met-enkephalin in the antinociception induced by intracerebroventricularly administered bremazocine but not morphine in the mouse.." The Journal of pharmacology and experimental therapeutics, 1993.
RethinkPeptides
RethinkPeptides Research Database. "Spinal involvement of both dynorphin A and Met-enkephalin in..." RPEP-00281. Retrieved from https://rethinkpeptides.com/research/tseng-1993-spinal-involvement-of-both
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.